Pyrosequencing for EGFR mutation detection: Diagnostic accuracy and clinical implications

Diagnostic Molecular Pathology

Volumn 22, Issue 4, 2013, Pages 196-203

  Sahnane, Nora ^a   Gueli, Rossana ^b   Tibiletti, Maria G ^a   Bernasconi, Barbara ^a   Stefanoli, Michele ^a   Franzi, Francesca ^a   Pinotti, Graziella ^b   Capella, Carlo ^a   Furlan, Daniela ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b OSPEDALE DI CIRCOLO   (Italy)

Author keywords

EGFR mutations; Non small cell lung cancer; Pyrosequencing; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER CONTROL; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIDEOXY SEQUENCING; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENETIC ANALYZER; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PYROSEQUENCING; RETROSPECTIVE STUDY; TITRIMETRY; TREATMENT RESPONSE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PATHOLOGY, MOLECULAR; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

EID: 84892709521     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e3182893f55     Document Type: Article

References (23)

1. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169-181.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med. 2004;350: 2129-2139.
3. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306-13311.
4. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643-655.
5. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23:6829-6837.
6. Liang Z, Zhang J, Zeng X, et al. Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer. 2010;10:376-384.
7. Dahabreh IJ, Linardou H, Kosmidis P, et al. EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-Analysis in non-small-cell lung cancer. Ann Oncol. 2011;22:545-552.
8. Querings S, Altmuller J, Ansen S, et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One. 2011; 6:e19601.
9. Dufort S, Richard MJ, Lantuejoul S, et al. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res. 2011;30:57-63.
10. Zhou Z, Poe AC, Limor J, et al. Pyrosequencing, a high-Throughput method for detecting single nucleotide polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum. J Clin Microbiol. 2006;44:3900-3910.
11. Shaw RJ, Hall GL, Lowe D, et al. The role of pyrosequencing in head and neck cancer epigenetics: correlation of quantitative methylation data with gene expression. Arch Otolaryngol Head Neck Surg. 2008;134:251-256.
12. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of lung cancer/American Thoracic Society/European Respiratory Society International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285.
13. Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
14. Kato Y, Peled N, Wynes MW, et al. Novel EGFR mutation specific antibodies for NSCLC: immunohistochemistry as a possible screening method for EGFR mutations. J Thorac Oncol. 2010;5: 1551-1558.
15. Suda K, Murakami I, Katayama T, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res. 2010;16:5489-5498.
16. Bernasconi B, Chiaravalli AM, Finzi G, et al. Genetic heterogeneity in HER2 testing may influence therapy eligibility. Breast Cancer Res Treat. 2011;133:161-168.
17. Gately K, O'Flaherty J, Cappuzzo F, et al. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC. J Clin Pathol. 2012;65:1-7.
18. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn. 2005;7:413-421.
19. Schumacher JA, Szankasi P, Bahler DW, et al. A pyrosequencingbased test for detection and relative quantification of the BCRABL1 T315I point mutation. J Clin Pathol. 2011;64:618-625.
20. Mikeska T, Bock C, El-Maarri O, et al. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn. 2007;9: 368-381.
21. Setty P, Hammes J, Rothamel T, et al. A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. J Mol Diagn. 2010;12:750-756.
22. Soh J, Okumura N, Lockwood WW, et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One. 2009;4:e7464.
23. Yatabe Y, Takahashi T, Mitsudomi T, et al. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res. 2008;68:2106-2111.